Interestingly, depletion of CD4+ T cells completely abrogated the anti-tumor efficacy of the class II HER2-DC1 alone or in combination with anti-PD-1 therapy suggesting the crucial role of CD4+ T cells. This evidence concerns the gene ERBB2 and neoplasm.